Symbols / SNTI
SNTI Chart
About
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 22.57M |
| Enterprise Value | 39.91M | Income | -50.10M | Sales | — |
| Book/sh | 0.31 | Cash/sh | 0.49 | Dividend Yield | — |
| Payout | 0.00% | Employees | 34 | IPO | — |
| P/E | — | Forward P/E | -0.62 | PEG | — |
| P/S | — | P/B | 2.78 | P/C | — |
| EV/EBITDA | -0.71 | EV/Sales | — | Quick Ratio | 1.21 |
| Current Ratio | 1.51 | Debt/Eq | 370.90 | LT Debt/Eq | — |
| EPS (ttm) | -2.87 | EPS next Y | -1.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -67.77% |
| ROE | -3.95% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.29M |
| Shs Float | 9.72M | Short Float | 2.89% | Short Ratio | 2.58 |
| Short Interest | — | 52W High | 5.10 | 52W Low | 0.80 |
| Beta | 2.14 | Avg Volume | 1.67M | Volume | 60.45K |
| Target Price | $11.50 | Recom | None | Prev Close | $0.83 |
| Price | $0.86 | Change | 3.16% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.50
Mean price target
2. Current target
$0.88
Latest analyst target
3. DCF / Fair value
$-16.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.88
Low
$6.00
High
$15.00
Mean
$11.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-09 | main | Chardan Capital | Buy → Buy | $13 |
| 2025-11-21 | init | Leerink Partners | — → Outperform | $6 |
| 2025-10-14 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-06-12 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-06-06 | init | Laidlaw & Co. | — → Buy | $15 |
| 2025-05-02 | main | Chardan Capital | Buy → Buy | $12 |
| 2024-12-04 | main | Chardan Capital | Buy → Buy | $12 |
| 2024-12-02 | main | Chardan Capital | Buy → Buy | $10 |
| 2023-08-15 | reit | Chardan Capital | Buy → Buy | $6 |
| 2023-05-11 | main | Chardan Capital | Buy → Buy | $6 |
| 2023-03-24 | main | Morgan Stanley | — → Equal-Weight | $2 |
| 2023-03-23 | main | Chardan Capital | — → Buy | $7 |
| 2023-01-30 | main | Chardan Capital | — → Buy | $8 |
| 2023-01-27 | main | Morgan Stanley | — → Equal-Weight | $3 |
| 2022-12-16 | init | JP Morgan | — → Neutral | — |
| 2022-10-07 | init | Morgan Stanley | — → Equal-Weight | $8 |
| 2022-09-29 | init | B of A Securities | — → Buy | $7 |
| 2022-09-23 | init | Chardan Capital | — → Buy | $12 |
- Leukemia cell therapy SENTI-202 heads for FDA talks after early remissions - Stock Titan Wed, 11 Feb 2026 13
- Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade ue, 09 Dec 2025 15
- New Analyst Forecast: $SNTI Given $13 Price Target - Quiver Quantitative ue, 09 Dec 2025 08
- SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment - Stocktwits ue, 09 Dec 2025 14
- Why Is Senti Biosciences Stock (SNTI) Up Today? - TipRanks ue, 09 Dec 2025 08
- What analyst consensus says on SNTI stock - 2025 Stock Rankings & Consistent Growth Equity Picks - mfd.ru Sat, 14 Feb 2026 03
- Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up - Nasdaq ue, 09 Dec 2025 08
- Senti Bio stock soars after positive cancer therapy trial results By Investing.com - Investing.com Nigeria Fri, 12 Sep 2025 07
- Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Senti Biosciences (NASDAQ:SNTI) - Benzinga ue, 09 Dec 2025 08
- Senti Biosciences (Nasdaq: SNTI) data show 42% CR/CRh, 7.6-mo remissions in AML - Stock Titan ue, 09 Dec 2025 08
- Senti Biosciences’ Surge: Buy or Wait? - timothysykes.com ue, 09 Dec 2025 08
- Senti Biosciences stock rating initiated at Buy by H.C. Wainwright - Investing.com ue, 14 Oct 2025 07
- Senti Biosciences Reports Third Quarter 2025 Financial Results and Pipeline Updates - Quiver Quantitative hu, 13 Nov 2025 08
- Senti Bio (Nasdaq: SNTI) gains FDA RMAT for SENTI-202 after 50% ORR in AML trial - Stock Titan ue, 09 Dec 2025 08
- Senti Biosciences: Understanding the Market Moves - StocksToTrade Wed, 10 Dec 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3333000 | — | — | NEW ENTERPRISE ASSOCIATES 15, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-10 00:00:00 | I | nan |
| 1 | 33000 | — | Conversion of Exercise of derivative security at price 2.25 per share. | RAJANGAM KANYA | President | — | 2025-03-10 00:00:00 | I | 74250.0 |
| 2 | 2222000 | — | — | BAYER HEALTHCARE L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-10 00:00:00 | I | nan |
| 3 | 9777000 | — | — | CELADON PARTNERS SPV 24 | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-10 00:00:00 | D | nan |
| 4 | 78363 | — | Stock Award(Grant) at price 0.00 per share. | RAJANGAM KANYA | President | — | 2025-03-07 00:00:00 | D | — |
| 5 | 642358 | — | Stock Award(Grant) at price 0.00 per share. | LU TIMOTHY K M.D., PH.D. | Chief Executive Officer | — | 2025-03-07 00:00:00 | D | — |
| 6 | 1479 | — | Sale at price 4.07 - 4.37 per share. | RAJANGAM KANYA | President | — | 2025-02-06 00:00:00 | D | 6074.0 |
| 7 | 4467 | — | Sale at price 4.07 - 4.36 per share. | LU TIMOTHY K M.D., PH.D. | Chief Executive Officer | — | 2025-02-06 00:00:00 | D | 18339.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -41.86M | -39.54M | -68.91M | -37.41M |
| TotalUnusualItems | -13.02M | -21.80M | 10.75M | -22.00K |
| TotalUnusualItemsExcludingGoodwill | -13.02M | -21.80M | 10.75M | -22.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -52.79M | -83.41M | -49.66M | -55.32M |
| ReconciledDepreciation | 5.85M | 5.43M | 3.92M | 3.01M |
| EBITDA | -54.88M | -61.34M | -58.16M | -37.44M |
| EBIT | -60.73M | -66.77M | -62.08M | -40.45M |
| NetInterestIncome | 948.00K | 2.86M | 1.70M | 11.00K |
| InterestIncome | 948.00K | 2.86M | 1.70M | 11.00K |
| NormalizedIncome | -39.77M | -61.61M | -60.41M | -55.30M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -52.79M | -71.06M | -58.21M | -55.32M |
| TotalExpenses | 60.73M | 68.74M | 65.37M | 42.74M |
| TotalOperatingIncomeAsReported | -61.04M | -92.73M | -62.08M | -40.45M |
| DilutedAverageShares | 4.60M | 4.44M | 2.61M | 4.37M |
| BasicAverageShares | 4.60M | 4.44M | 2.61M | 4.37M |
| DilutedEPS | -12.03 | -16.01 | -22.30 | -12.67 |
| BasicEPS | -12.03 | -16.01 | -22.30 | -12.67 |
| DilutedNIAvailtoComStockholders | -52.79M | -71.06M | -58.21M | -55.32M |
| NetIncomeCommonStockholders | -52.79M | -71.06M | -58.21M | -55.32M |
| NetIncome | -52.79M | -71.06M | -58.21M | -55.32M |
| NetIncomeIncludingNoncontrollingInterests | -52.79M | -71.06M | -58.21M | -55.32M |
| NetIncomeDiscontinuousOperations | 0.00 | 12.35M | -8.54M | |
| NetIncomeContinuousOperations | -52.79M | -83.41M | -49.66M | -55.32M |
| PretaxIncome | -52.79M | -83.41M | -49.66M | -55.32M |
| OtherIncomeExpense | 6.99M | -19.50M | 10.72M | -14.88M |
| OtherNonOperatingIncomeExpenses | 20.01M | 2.29M | -32.00K | -14.86M |
| SpecialIncomeCharges | -293.00K | -25.75M | 10.75M | -22.00K |
| OtherSpecialCharges | -1.29M | |||
| ImpairmentOfCapitalAssets | 313.00K | 25.96M | 0.00 | 22.00K |
| RestructuringAndMergernAcquisition | -20.00K | -207.00K | -9.46M | 0.00 |
| GainOnSaleOfSecurity | -12.72M | 3.96M | ||
| NetNonOperatingInterestIncomeExpense | 948.00K | 2.86M | 1.70M | 11.00K |
| InterestIncomeNonOperating | 948.00K | 2.86M | 1.70M | 11.00K |
| OperatingIncome | -60.73M | -66.77M | -62.08M | -40.45M |
| OperatingExpense | 60.73M | 68.74M | 65.37M | 42.74M |
| OtherOperatingExpenses | -583.00K | -1.00M | -470.00K | |
| DepreciationAmortizationDepletionIncomeStatement | 2.86M | 2.31M | 592.00K | |
| DepreciationAndAmortizationInIncomeStatement | 2.86M | 2.31M | 592.00K | |
| ResearchAndDevelopment | 34.36M | 32.15M | 28.14M | 21.96M |
| SellingGeneralAndAdministration | 23.51M | 34.87M | 37.63M | 21.25M |
| GeneralAndAdministrativeExpense | 23.51M | 34.87M | 37.63M | 21.25M |
| OtherGandA | 15.13M | 11.75M | 8.91M | 9.37M |
| InsuranceAndClaims | 1.66M | 1.21M | 127.00K | |
| SalariesAndWages | 8.38M | 23.12M | 27.51M | 11.76M |
| TotalRevenue | 0.00 | 1.98M | 3.29M | 2.29M |
| OperatingRevenue | 0.00 | 1.98M | 3.29M | 2.29M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 4.83M | 4.57M | 4.41M | 4.37M |
| ShareIssued | 4.83M | 4.57M | 4.41M | 4.37M |
| TotalDebt | 33.64M | 37.67M | 37.09M | 22.73M |
| TangibleBookValue | 25.65M | 66.91M | 127.26M | -111.46M |
| InvestedCapital | 25.65M | 66.91M | 127.26M | -111.46M |
| WorkingCapital | 45.81M | 58.53M | 84.53M | 45.65M |
| NetTangibleAssets | 25.65M | 66.91M | 127.26M | -111.46M |
| CapitalLeaseObligations | 33.64M | 37.67M | 37.09M | 22.73M |
| CommonStockEquity | 25.65M | 66.91M | 127.26M | -111.46M |
| TotalCapitalization | 25.65M | 66.91M | 127.26M | -111.46M |
| TotalEquityGrossMinorityInterest | 25.65M | 66.91M | 127.26M | -111.46M |
| StockholdersEquity | 25.65M | 66.91M | 127.26M | -111.46M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 1.00K | 0.00 | |
| OtherEquityAdjustments | 1.00K | |||
| RetainedEarnings | -297.13M | -244.34M | -173.29M | -115.08M |
| AdditionalPaidInCapital | 322.78M | 311.26M | 300.54M | 3.62M |
| CapitalStock | 1.00K | 1.00K | 4.00K | 0.00 |
| CommonStock | 1.00K | 1.00K | 4.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 72.19M | 52.57M | 53.53M | 208.16M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 59.05M | 39.90M | 35.48M | 193.62M |
| OtherNonCurrentLiabilities | 5.05M | 20.00K | 227.00K | |
| PreferredSecuritiesOutsideStockEquity | 25.11M | 0.00 | 0.00 | 171.83M |
| DerivativeProductLiabilities | 0.00 | 6.34M | 146.00K | 619.00K |
| NonCurrentDeferredLiabilities | 0.00 | 176.00K | ||
| NonCurrentDeferredRevenue | 0.00 | 176.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 28.89M | 33.54M | 35.10M | 20.99M |
| LongTermCapitalLeaseObligation | 28.89M | 33.54M | 35.10M | 20.99M |
| CurrentLiabilities | 13.15M | 12.67M | 18.05M | 14.54M |
| OtherCurrentLiabilities | 11.00K | 378.00K | 1.32M | 626.00K |
| CurrentDeferredLiabilities | 660.00K | 989.00K | 799.00K | 1.66M |
| CurrentDeferredRevenue | 660.00K | 989.00K | 799.00K | 1.66M |
| CurrentDebtAndCapitalLeaseObligation | 4.75M | 4.13M | 1.99M | 1.74M |
| CurrentCapitalLeaseObligation | 4.75M | 4.13M | 1.99M | 1.74M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.54M | 2.36M | 1.71M | 2.67M |
| PayablesAndAccruedExpenses | 5.18M | 4.81M | 12.24M | 7.85M |
| CurrentAccruedExpenses | 3.73M | 3.56M | 10.87M | 2.67M |
| Payables | 1.45M | 1.25M | 1.37M | 5.19M |
| AccountsPayable | 1.45M | 1.25M | 1.37M | 5.19M |
| TotalAssets | 97.84M | 119.48M | 180.79M | 96.70M |
| TotalNonCurrentAssets | 38.88M | 48.28M | 78.21M | 36.51M |
| OtherNonCurrentAssets | 3.64M | 3.74M | 8.43M | 3.43M |
| DuefromRelatedPartiesNonCurrent | 0.00 | 2.94M | 0.00 | |
| NonCurrentAccountsReceivable | 2.94M | |||
| NetPPE | 35.24M | 41.61M | 69.78M | 33.08M |
| AccumulatedDepreciation | -9.55M | -6.18M | -2.96M | -1.66M |
| GrossPPE | 44.79M | 47.79M | 72.73M | 34.73M |
| Leases | 22.66M | 22.65M | 1.87M | 431.00K |
| ConstructionInProgress | 0.00 | 43.89M | 8.05M | |
| OtherProperties | 21.50M | 24.46M | 26.27M | 25.70M |
| MachineryFurnitureEquipment | 630.00K | 686.00K | 700.00K | 556.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 58.96M | 71.20M | 102.58M | 60.19M |
| OtherCurrentAssets | 584.00K | 195.00K | 101.00K | 275.00K |
| AssetsHeldForSaleCurrent | 0.00 | 209.00K | ||
| CurrentDeferredAssets | 0.00 | 1.45M | ||
| PrepaidAssets | 8.29M | 17.38M | 3.08M | 1.96M |
| Receivables | 1.80M | 17.70M | 626.00K | 483.00K |
| DuefromRelatedPartiesCurrent | 1.65M | 17.59M | 0.00 | |
| AccountsReceivable | 159.00K | 112.00K | 626.00K | 483.00K |
| CashCashEquivalentsAndShortTermInvestments | 48.28M | 35.93M | 98.56M | 56.03M |
| OtherShortTermInvestments | 0.00 | 40.94M | 0.00 | |
| CashAndCashEquivalents | 48.28M | 35.93M | 57.62M | 56.03M |
| CashEquivalents | 35.87M | 31.72M | 56.03M | |
| CashFinancial | 12.41M | 4.21M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -41.42M | -64.43M | -76.27M | -40.18M |
| RepaymentOfDebt | 0.00 | -108.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 5.17M | 0.00 | |
| IssuanceOfCapitalStock | 49.06M | 512.00K | 728.00K | 66.95M |
| CapitalExpenditure | -26.00K | -12.04M | -41.37M | -5.54M |
| EndCashPosition | 51.81M | 39.45M | 60.99M | 59.29M |
| BeginningCashPosition | 39.45M | 60.99M | 59.29M | 31.03M |
| ChangesInCash | 12.37M | -21.54M | 1.70M | 28.26M |
| FinancingCashFlow | 53.73M | 779.00K | 118.55M | 68.44M |
| CashFlowFromContinuingFinancingActivities | 53.73M | 779.00K | 118.55M | 68.44M |
| NetOtherFinancingCharges | 4.67M | 111.98M | -17.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 375.00K | 672.00K | 1.50M |
| NetPreferredStockIssuance | 0.00 | 66.95M | ||
| PreferredStockIssuance | 0.00 | 66.95M | ||
| NetCommonStockIssuance | 49.06M | 512.00K | 728.00K | 0.00 |
| CommonStockIssuance | 49.06M | 512.00K | 728.00K | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -108.00K | 5.17M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | -108.00K | 5.17M | 0.00 |
| LongTermDebtPayments | 0.00 | -108.00K | 0.00 | |
| LongTermDebtIssuance | 0.00 | 5.17M | 0.00 | |
| InvestingCashFlow | 34.00K | 30.08M | -81.96M | -5.54M |
| CashFlowFromContinuingInvestingActivities | 34.00K | 30.08M | -81.96M | -5.54M |
| NetInvestmentPurchaseAndSale | 0.00 | 42.01M | -40.59M | 0.00 |
| SaleOfInvestment | 0.00 | 60.00M | 0.00 | 0.00 |
| PurchaseOfInvestment | 0.00 | -17.99M | -40.59M | 0.00 |
| NetPPEPurchaseAndSale | 34.00K | -11.93M | -41.37M | -5.54M |
| SaleOfPPE | 60.00K | 105.00K | 0.00 | |
| PurchaseOfPPE | -26.00K | -12.04M | -41.37M | -5.54M |
| OperatingCashFlow | -41.40M | -52.40M | -34.90M | -34.63M |
| CashFlowFromContinuingOperatingActivities | -41.40M | -52.40M | -34.90M | -34.63M |
| ChangeInWorkingCapital | 4.04M | 4.67M | 13.90M | 615.00K |
| ChangeInOtherWorkingCapital | -329.00K | -110.00K | -1.03M | 1.83M |
| ChangeInOtherCurrentLiabilities | -3.88M | 484.00K | 14.13M | -1.14M |
| ChangeInPayablesAndAccruedExpense | 126.00K | 426.00K | 2.24M | 1.96M |
| ChangeInAccruedExpense | -671.00K | 716.00K | 2.06M | 2.57M |
| ChangeInPayable | 797.00K | -290.00K | 186.00K | -617.00K |
| ChangeInAccountPayable | 797.00K | -290.00K | 186.00K | -617.00K |
| ChangeInPrepaidAssets | 8.86M | 4.79M | -1.30M | -1.64M |
| ChangeInReceivables | -727.00K | -929.00K | -131.00K | -395.00K |
| ChangesInAccountReceivables | -62.00K | 507.00K | -131.00K | -395.00K |
| OtherNonCashItems | 5.76M | -814.00K | -9.61M | 14.74M |
| StockBasedCompensation | 1.75M | 9.67M | 16.39M | 2.29M |
| AssetImpairmentCharge | 313.00K | 25.96M | 12.00K | 22.00K |
| AmortizationOfSecurities | 0.00 | -1.07M | -356.00K | 0.00 |
| DepreciationAmortizationDepletion | 5.85M | 5.43M | 3.92M | 3.01M |
| DepreciationAndAmortization | 5.85M | 5.43M | 3.92M | 3.01M |
| Depreciation | 5.85M | 5.43M | 3.92M | 3.01M |
| OperatingGainsLosses | -6.33M | -25.18M | -1.29M | |
| GainLossOnInvestmentSecurities | -6.33M | -3.32M | ||
| GainLossOnSaleOfBusiness | 0.00 | -21.86M | 0.00 | |
| NetIncomeFromContinuingOperations | -52.79M | -71.06M | -58.22M | -55.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SNTI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|